1. Home
  2. QMLS vs ADAG Comparison

QMLS vs ADAG Comparison

Compare QMLS & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

QMLS

QumulusAI Inc. Common Stock

HOLD

Current Price

$3.76

Market Cap

210.4M

Sector

Technology

ML Signal

HOLD

Logo Adagene Inc.

ADAG

Adagene Inc.

HOLD

Current Price

$2.07

Market Cap

222.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
QMLS
ADAG
Founded
2019
2011
Country
United States
China
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
210.4M
222.2M
IPO Year
2025
2020

Fundamental Metrics

Financial Performance
Metric
QMLS
ADAG
Price
$3.76
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
★ $9.91
AVG Volume (30 Days)
★ 454.3K
365.5K
Earning Date
11-25-2026
08-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$349.31
N/A
Revenue Next Year
$782.64
$129.59
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.70
$1.30
52 Week High
$14.82
$4.85

Technical Indicators

Market Signals
Indicator
QMLS
ADAG
Relative Strength Index (RSI) 30.60 25.96
Support Level N/A $1.50
Resistance Level $7.66 $3.40
Average True Range (ATR) 0.62 0.27
MACD -0.26 -0.06
Stochastic Oscillator 2.67 7.88

Price Performance

Historical Comparison
QMLS
ADAG

About QMLS QumulusAI Inc. Common Stock

QumulusAI Inc is a cloud infrastructure company engaged in the rapid deployment of graphics processing unit (GPU)-powered solutions for artificial intelligence (AI) applications, serving a critical market that is often overlooked by large-scale cloud providers (hyperscalers), which operate massive, standardized computing infrastructures serving the immense enterprises. The platform delivers flexible, competitively priced, and customizable solutions for underserved small- and mid-market customers, including machine learning teams, AI infrastructure startups, and research institutions, and also supports the scale and complexity requirements of large enterprises. Its products are B300 SXM6, B200 SXM, RTX Pro 6000, H200 SXM, and Others. Its solutions are Enterprise, Research, and AI Startups.

About ADAG Adagene Inc.

Adagene Inc is a platform-driven, clinical-stage biotechnology company focused on the discovery and development of novel antibody-based cancer immunotherapies. The Company leverages computational biology to design and develop novel antibodies. Powered by its Dynamic Precision Library (DPL) platform, which fuels its NEObody, SAFEbody, and POWERbody technologies, it is developing a pipeline of immunotherapies. Its candidate, ADG126 (muzastotug), an anti-CTLA-4 SAFEbody, is in phase 1b/2 and phase 2 clinical development for metastatic microsatellite-stable colorectal cancer. Its clinical-stage products include ADG126 and ADG116, investigational fully human anti-CTLA-4 mAbs generated through SAFEbody and NEObody technologies.

Share on Social Networks: